These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23598371)

  • 1. Randomised trial on episodic cluster headache with an angiotensin II receptor blocker.
    Tronvik E; Wienecke T; Monstad I; Dahløf C; Bøe MG; Tjensvoll AB; Salvesen R; Zwart JA; Jansson SO; Stovner LJ
    Cephalalgia; 2013 Sep; 33(12):1026-34. PubMed ID: 23598371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
    Chaturvedi N; Porta M; Klein R; Orchard T; Fuller J; Parving HH; Bilous R; Sjølie AK;
    Lancet; 2008 Oct; 372(9647):1394-402. PubMed ID: 18823656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
    Tronvik E; Stovner LJ; Helde G; Sand T; Bovim G
    JAMA; 2003 Jan; 289(1):65-9. PubMed ID: 12503978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ; Bailey EK; Reed AN; Gales MA
    Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
    Radke PW; Figulla HR; Drexler H; Klues HG; Mügge A; Silber S; Daniel W; Schmeisser A; Reifart N; Motz W; Büttner HJ; Fischer D; Ortlepp JR; Schaefers K; Hoffmann R; Hanrath P;
    Am Heart J; 2006 Oct; 152(4):761.e1-6. PubMed ID: 16996855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
    Flesch M; Knipp S; Kessler G; Geissler HJ; Massoudy P; Wilhelm H; Philipp T; Erdmann E
    Clin Res Cardiol; 2009 Jan; 98(1):33-43. PubMed ID: 18853093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial.
    Leroux E; Valade D; Taifas I; Vicaut E; Chagnon M; Roos C; Ducros A
    Lancet Neurol; 2011 Oct; 10(10):891-7. PubMed ID: 21903477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.
    Granger BB; Swedberg K; Ekman I; Granger CB; Olofsson B; McMurray JJ; Yusuf S; Michelson EL; Pfeffer MA;
    Lancet; 2005 Dec; 366(9502):2005-11. PubMed ID: 16338449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial--a multicenter study of AT1-receptor blocker therapy in coronary stenting.
    Krämer J; Ruf RG; Schmidt S; Axthelm C; Strasser R; Janssen G; Thieme T; Kusch A; Waigand J; Dietz R; Gross CM
    J Invasive Cardiol; 2008 May; 20(5):205-10. PubMed ID: 18460701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candesartan in the prevention of relapsing atrial fibrillation.
    Tveit A; Grundvold I; Olufsen M; Seljeflot I; Abdelnoor M; Arnesen H; Smith P
    Int J Cardiol; 2007 Aug; 120(1):85-91. PubMed ID: 17113170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.